Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

648 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Remission and regression of diabetic nephropathy.
Hovind P, Tarnow L, Parving HH. Hovind P, et al. Curr Hypertens Rep. 2004 Oct;6(5):377-82. doi: 10.1007/s11906-004-0057-x. Curr Hypertens Rep. 2004. PMID: 15341691 Review.
Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes.
Persson F, Theilade S, Eugen-Olsen J, Rossing P, Parving HH. Persson F, et al. J Diabetes Complications. 2016 Nov-Dec;30(8):1440-1442. doi: 10.1016/j.jdiacomp.2016.07.003. Epub 2016 Jul 16. J Diabetes Complications. 2016. PMID: 27475262 Clinical Trial.
Direct renin inhibition in chronic kidney disease.
Persson F, Rossing P, Parving HH. Persson F, et al. Br J Clin Pharmacol. 2013 Oct;76(4):580-6. doi: 10.1111/bcp.12072. Br J Clin Pharmacol. 2013. PMID: 23278708 Free PMC article. Review.
Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study.
Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Persson F, et al. J Renin Angiotensin Aldosterone Syst. 2012 Jun;13(2):250-3. doi: 10.1177/1470320312437068. Epub 2012 Feb 16. J Renin Angiotensin Aldosterone Syst. 2012. PMID: 22345094 Clinical Trial.
Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.
Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, Parving I, Pietraszek L, Frandsen M, Rossing P, Parving HH, Vaag AA. Lund SS, et al. PLoS One. 2008;3(10):e3363. doi: 10.1371/journal.pone.0003363. Epub 2008 Oct 9. PLoS One. 2008. PMID: 18852875 Free PMC article. Clinical Trial.
Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.
Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O. Gaede P, et al. Diabetes Care. 2008 Aug;31(8):1510-5. doi: 10.2337/dc07-2452. Epub 2008 Apr 28. Diabetes Care. 2008. PMID: 18443195 Free PMC article.
Increased all-cause mortality in patients with type 1 diabetes and high-expression mannan-binding lectin genotypes: a 12-year follow-up study.
Østergaard JA, Thiel S, Lajer M, Steffensen R, Parving HH, Flyvbjerg A, Rossing P, Tarnow L, Hansen TK. Østergaard JA, et al. Diabetes Care. 2015 Oct;38(10):1898-903. doi: 10.2337/dc15-0851. Epub 2015 Jul 15. Diabetes Care. 2015. PMID: 26180106
A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study.
Gæde J, Oellgaard J, Ibsen R, Gæde P, Nørtoft E, Parving HH, Kjellberg J, Pedersen O. Gæde J, et al. Diabetologia. 2019 Jan;62(1):147-155. doi: 10.1007/s00125-018-4739-3. Epub 2018 Oct 6. Diabetologia. 2019. PMID: 30293113 Free PMC article.
High YKL-40 levels predict mortality in patients with type 2 diabetes.
Persson F, Rathcke CN, Gall MA, Parving HH, Vestergaard H, Rossing P. Persson F, et al. Diabetes Res Clin Pract. 2012 Apr;96(1):84-9. doi: 10.1016/j.diabres.2011.12.008. Epub 2011 Dec 31. Diabetes Res Clin Pract. 2012. PMID: 22209020
648 results
Jump to page